BioSpace News Archive

Drug Development

AbbVie Clinches Back-to-Back Clinical Wins in Ulcerative Colitis, Lupus

In a double data drop Thursday, AbbVie touted two clinical trial wins, for Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus.

March 24, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Relmada Looks to Rebound with New Protocol After Two Phase III Flops

Relmada Therapeutics announced it would make key changes to its clinical evaluation of REL-1017 as a possible add-on treatment for major depressive disorder.

March 24, 2023
·
2 min read
·
Ana Mulero
Drug Development

Latest Data for Karuna’s Schizophrenia Drug Spark Investor Concern

Analysts point to a missed secondary endpoint and cardiovascular risks that may delay FDA approval as possible reasons for the unexpected drop in Karuna’s stock following the data reveal.

March 24, 2023
·
4 min read
·
Kate Goodwin
Policy

FDA Action Alert: Roche, Emergent and More

The FDA is expected to make decisions on Emergent BioSolutions’ sNDA for OTC Narcan and Roche’s Polivy in frontline DLBCL.

March 24, 2023
·
3 min read
·
Tristan Manalac
Policy

NICE Backs PTC’s Gene Therapy for Ultra-Rare Pediatric Disease

Upstaza is the first targeted therapy for aromatic L-amino acid decarboxylase (AADC) deficiency. PTC expects to submit a Biologics License Application to the FDA in the first half of 2023.

March 24, 2023
·
2 min read
·
Tristan Manalac
Philips convenes the Annual General Meeting of Shareholders 2023

Royal Philips announced it has convened the Annual General Meeting of Shareholders 2023 and published the agenda with explanatory notes.

March 24, 2023
·
3 min read
BioForest

Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis

Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis.

March 24, 2023
·
6 min read
Business

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Ryvu Therapeutics reported financial results for the fourth quarter and the full year ended December 31, 2022, and provided a corporate update.

March 24, 2023
·
9 min read
Genetown

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

Allarity Therapeutics, Inc. announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post split share for every 35 pre-split shares.

March 24, 2023
·
8 min read
Genetown

HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

HiberCell today announced three pre-clinical poster presentations which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

March 24, 2023
·
4 min read